Hikal Limited
Financial trend (100/100) does the heavy lifting; quality (48/100) is the drag.
Buy zoneStocksWizard rates Hikal Limited a Buy, scoring 73/100 on our blended model. We put fair value near ₹345.08; at ₹212.22 that leaves roughly 63% upside, so the stock screens undervalued by 63%. On 24.3x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹269.09 and 45% above the low of ₹146.84. Financial health scores 44/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹300 implies about 41% upside across 1 analysts. It clears 6 of 10 investability checks, with durability 48, valuation 82 and momentum 54 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹276.07.
Analyst views
1-year price
EOD · 2026-09-1552-week range
-21.14% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy73Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- No data: Low debt (D/E < 0.5)
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 37%
- Pass: Earnings growing: 68%
- Fail: Net margin ≥ 10%: 6.2%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.78
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter69.1%
- Institutions7.9%
- Public & other23.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Earnings growing (68% YoY).
- Revenue growing (37% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~63% below our estimated fair value.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
About Hikal Limited
Hikal Limited manufactures chemical intermediates, specialty chemicals, and active pharmaceutical ingredients for pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemical industries. The company operates through Pharmaceuticals and Crop Protection segments, producing pesticides and herbicides including diuron, temephos, thiacloprid, and clothianidin technical products.
Hikal Limited — frequently asked questions
Is Hikal Limited a buy, hold or sell?
StocksWizard currently rates Hikal Limited (HIKAL) a Buy, based on a blended score of 73/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Hikal Limited's fair value?
Our blended DCF and relative-valuation model estimates Hikal Limited's fair value at about ₹345.08, versus a current price of ₹212.22 — roughly 63% upside. On that basis the stock looks undervalued by 63%.
Is Hikal Limited financially healthy?
Hikal Limited scores 44/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Hikal Limited's share price performed?
Hikal Limited is up 12% over three months, and last traded at ₹212.22. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.